摘要
Abstract
Objective:The Jianpi Huatan Qushi formula is a commonly used traditional Chinese medicine prescription.When used as an adjunct to chemotherapy,it may enhance the therapeutic efficacy in non-small cell lung cancer(NSCLC)and reduce adverse reactions.This study aims to evaluate the effect of the Jianpi Huatan Qushi formula on immune function,treatment efficacy,and prognosis in NSCLC patients with a traditional Chinese medicine diagnosis of spleen deficiency with phlegm-dampness undergoing concurrent chemoradiotherapy.
Methods:A total of 72 NSCLC patients treated at Pingdingshan Second People's Hospital between December 2020 and January 2023 were enrolled and divided into a control group(n=36)receiving standard concurrent chemoradiotherapy,and an observation group(n=36)receiving the same treatment plus oral Jianpi Huatan Qushi formula.The 2 groups were compared in terms of short-term efficacy,immune markers(CD3+,CD4+,CD8+,CD4+/CD8+),tumor markers,traditional Chinese medicine syndrome scores,SF-36 quality of life scores,and adverse reactions,and survival outcomes[progression-free survival(PFS)and overall survival(OS)].
Results:There were no significantly significant differences in overall response rate or disease control rate between the 2 groups(P>0.05).Post-treatment levels of carcinoma embryonic antigen(CEA),carbohydrate antigen 125(CA125),and neuron-specific enolase(NSE),as well as the incidence of alopecia,gastrointestinal reactions,myelosuppression,and diarrhea were significantly lower in the observation group.In contrast,the observation group had significantly higher levels of CD3+,CD4+,CD4+/CD8+ratio,better traditional Chinese medicine syndrome scores,and higher SF-36 quality of life scores(all P<0.05).Survival analysis showed that PFS was significantly longer in the observation group(χ2=5.313,P=0.021),while OS did not differ significantly(χ2=1.983,P=0.159).
Conclusion:The Jianpi Huatan Qushi formula,when combined with concurrent chemoradiotherapy,may improve immune function and prognosis in NSCLC patients,reduce serum tumor marker levels,and is associated with fewer adverse reactions.These findings suggest it has potential for broader clinical application.关键词
健脾化痰祛湿方/非小细胞肺癌/同步放化疗/疗效/免疫功能Key words
Jianpi Huatan Qushi formula/non-small cell lung cancer/concurrent chemoradiotherapy/therapeutic efficacy/immune function
